Impax Asset Management Group plc Sells 200,000 Shares of Roivant Sciences Ltd. $ROIV

Impax Asset Management Group plc trimmed its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 10.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,800,000 shares of the company’s stock after selling 200,000 shares during the period. Impax Asset Management Group plc owned 0.26% of Roivant Sciences worth $27,234,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its position in shares of Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after acquiring an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after purchasing an additional 34,341 shares during the last quarter. KLP Kapitalforvaltning AS grew its holdings in Roivant Sciences by 6.6% during the second quarter. KLP Kapitalforvaltning AS now owns 76,100 shares of the company’s stock worth $858,000 after purchasing an additional 4,700 shares during the period. Vanguard Personalized Indexing Management LLC increased its position in Roivant Sciences by 28.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 43,612 shares of the company’s stock worth $492,000 after buying an additional 9,548 shares during the last quarter. Finally, CWM LLC raised its stake in Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $27.35 on Wednesday. The firm has a 50-day moving average of $22.36 and a 200-day moving average of $18.08. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $27.94. The stock has a market cap of $19.02 billion, a PE ratio of -23.38 and a beta of 1.22.

Insider Activity

In other news, Director Daniel Allen Gold sold 1,300,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total transaction of $26,299,000.00. Following the transaction, the director directly owned 18,047,727 shares of the company’s stock, valued at approximately $365,105,517.21. This trade represents a 6.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Richard Pulik sold 406,731 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total value of $9,122,976.33. Following the completion of the sale, the chief financial officer owned 239,413 shares of the company’s stock, valued at approximately $5,370,033.59. This trade represents a 62.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 12,132,392 shares of company stock worth $262,349,645. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. HC Wainwright lifted their target price on Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday. The Goldman Sachs Group raised their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. Citigroup upped their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Leerink Partners lifted their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.